SCHEMBL7541339

SCHEMBL7541339

CC(C)C[CH]c1c[nH]c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.53
IMPDH2 P12268 1/20 0.53
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.49
HTR2A P28223 2/20 0.46
HTR2C P28335 2/20 0.46
HTR2B P41595 2/20 0.46
ADRB1 P08588 1/20 0.46
HTR1A P08908 1/20 0.46
ADRA2A P08913 1/20 0.46
SLC6A2 P23975 1/20 0.46
HTR1D P28221 1/20 0.46
HTR1B P28222 1/20 0.46
HTR1E P28566 1/20 0.46
SLC6A4 P31645 1/20 0.46
HTR7 P34969 1/20 0.46
HTR6 P50406 1/20 0.46
SLC6A3 Q01959 1/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3621033 0.82 CYP2A6 (0.60) CYP2A6IMPDH2HPGDHTTMEN1
SCHEMBL27283834 0.82 MAPT (0.59) CYP2A6IMPDH2HPGDHTTMEN1
SCHEMBL8614017 0.77 CYP2A6 (0.55) CYP2A6IMPDH2HPGDHTTMEN1
SCHEMBL27874251 0.77 CYP2A6 (0.58) CYP2A6IMPDH2HPGDHTTHTR2A
SCHEMBL27719415 0.77 CYP2A6 (0.58) CYP2A6IMPDH2HPGDHTTMEN1
SCHEMBL22925072 0.76 HTT (0.62) CYP2A6IMPDH2HPGDHTTMEN1
SCHEMBL11372556 0.75 CYP2A6 (0.56) CYP2A6IMPDH2HPGDHTTHTR2A
SCHEMBL7534323 0.75 GPR84 (0.51) CYP2A6IMPDH2HPGDHTTHTR2A
SCHEMBL9967720 0.74 CYP2A6 (0.55) CYP2A6IMPDH2HPGDHTTMEN1
SCHEMBL1959662 0.74 CYP2A6 (0.55) CYP2A6IMPDH2HPGDHTTSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1205181-C Matrix metalloproteinase inhibitors LEO PHARMACEUTICAL PRODUOTS LT (DK) 2005-06-08 CN disclosed
CN-1289323-A Matrix metalloproteinase inhibitors LEO PHARMACEUTICAL PRODUOTS LT (DK) 2001-03-28 CN disclosed
EP-0457195-B1 Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1998-04-15 EP disclosed
EP-0722321-A4 SULFOXIMINE AND SULFODIIMINE MATRIX METALLOPROTEINASE INHIBITORS UNIV FLORIDA STATE (US) 1998-04-15 EP disclosed
US-5656604-A HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-08-12 US disclosed
EP-0722321-A1 SULFOXIMINE AND SULFODIIMINE MATRIX METALLOPROTEINASE INHIBITORS FLORIDA STATE UNIVERSITY (US) 1996-07-24 EP disclosed
US-5430022-A Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-07-04 US disclosed
WO-1995009620-A1 SULFOXIMINE AND SULFODIIMINE MATRIX METALLOPROTEINASE INHIBITORS FLORIDA STATE UNIVERSITY (US) 1995-04-13 WO disclosed
US-5284828-A Hypotensive agents FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 1994-02-08 US disclosed
EP-0457195-A2 Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-11-21 EP disclosed